{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:24:07Z","timestamp":1787009047850,"version":"build-2736575974"},"reference-count":83,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) is a genetically heterogeneous disease where specific genetic abnormalities have a significant impact on a patient\u2019s prognosis. Diagnostic and prognostic tools like fluorescence in situ hybridization (FISH), PCR, microarrays, and next-generation sequencing (NGS) have transformed MM management. However, the effectiveness of these techniques is often limited by the low concentration of plasma cells in bone marrow samples, which makes enrichment methods necessary. This review aims to clarify how these techniques enhance the detection of genetic abnormalities, reduce false-negative results, and facilitate more precise risk stratification for MM patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Content<\/jats:title>\n                    <jats:p>Following Preferred Reporting Items for Systematic reviews and Meta-Analyses Extension for Scoping Review (PRISMA-ScR) guidelines, the literature on plasma cell separation methods used in genetic studies of MM was systematically identified and mapped. Searches were conducted in the Medline and Embase databases using a structured strategy, supplemented by manual searches on Google Scholar. Of 399 publications evaluated, 69 met the inclusion criteria; 37% utilized FISH and 19% demonstrated an increasing use of NGS. Plasma cell enrichment significantly improved diagnostic accuracy, increasing the detection rates of genetic abnormalities from 61% in non-enriched samples to 95.5% in enriched samples. While FISH remains the gold standard, emerging technologies such as NGS offer superior sensitivity and the ability to identify critical genetic alterations to refine molecular subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Clinically significant genetic alterations are detected more frequently with plasma cell enrichment techniques, contributing to improved prognosis and treatment strategies for MM patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jalm\/jfaf044","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T16:46:20Z","timestamp":1743353180000},"page":"1292-1310","source":"Crossref","is-referenced-by-count":3,"title":["Plasma Cell Enrichment and New Genomic Approaches in Multiple Myeloma: A Scoping Review"],"prefix":"10.1093","volume":"10","author":[{"given":"Juan Javier","family":"L\u00f3pez Rivera","sequence":"first","affiliation":[{"name":"Laboratorio Especializado en Biolog\u00eda Molecular, Cl\u00ednica Colsanitas, Grupo Keralty , Bogot\u00e1 ,","place":["Colombia"]},{"name":"Grupo de Gen\u00e9tica M\u00e9dica, Cl\u00ednica Universitaria Colombia, Cl\u00ednica Colsanitas, Grupo Keralty , Bogot\u00e1 ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0094-6421","authenticated-orcid":false,"given":"Natalia","family":"Gomez-Lopera","sequence":"additional","affiliation":[{"name":"Laboratorio Cl\u00ednico y de Patolog\u00eda, Cl\u00ednica Colsanitas, Grupo Keralty , Bogot\u00e1 ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Jennifer","family":"Moreno-Garcia","sequence":"additional","affiliation":[{"name":"Laboratorio Especializado en Biolog\u00eda Molecular, Cl\u00ednica Colsanitas, Grupo Keralty , Bogot\u00e1 ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Orduz-Rodriguez","sequence":"additional","affiliation":[{"name":"Laboratorio Cl\u00ednico y de Patolog\u00eda, Cl\u00ednica Colsanitas, Grupo Keralty , Bogot\u00e1 ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan F","family":"Combariza-Vallejo","sequence":"additional","affiliation":[{"name":"Servicio de Hematolog\u00eda, Cl\u00ednica Universitaria Colombia, Cl\u00ednica Colsanitas S.A., Grupo Keralty , Bogot\u00e1 ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Isaza-Ruget","sequence":"additional","affiliation":[{"name":"Laboratorio Cl\u00ednico y de Patolog\u00eda, Cl\u00ednica Colsanitas, Grupo Keralty , Bogot\u00e1 ,","place":["Colombia"]},{"name":"Unidad de Investigaci\u00f3n, Fundaci\u00f3n Universitaria Sanitas, Grupo de investigaci\u00f3n INPAC, Grupo Keralty , Bogot\u00e1 ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"key":"2025090311533938400_jfaf044-B1","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"2025090311533938400_jfaf044-B2","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.4049\/jimmunol.1202493","article-title":"Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis","volume":"190","author":"Heuck","year":"2013","journal-title":"J Immunol"},{"key":"2025090311533938400_jfaf044-B3","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025090311533938400_jfaf044-B4","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"2025090311533938400_jfaf044-B5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"2025090311533938400_jfaf044-B6","doi-asserted-by":"crossref","first-page":"101168","DOI":"10.1016\/j.blre.2024.101168","article-title":"Chromosomal defects in multiple myeloma","volume":"64","author":"Clarke","year":"2024","journal-title":"Blood Rev"},{"key":"2025090311533938400_jfaf044-B7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.5858\/arpa.2012-0209-OA","article-title":"Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms","volume":"137","author":"Lu","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"2025090311533938400_jfaf044-B8","doi-asserted-by":"crossref","first-page":"E473","DOI":"10.1002\/ajh.24533","article-title":"Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma","volume":"91","author":"Merz","year":"2016","journal-title":"Am J Hematol"},{"key":"2025090311533938400_jfaf044-B9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cancergen.2020.01.001","article-title":"The combination of WGS and RNA-Seq is superior to conventional diagnostic tests in multiple myeloma: ready for prime time?","volume":"242","author":"H\u00f6llein","year":"2020","journal-title":"Cancer Genet"},{"key":"2025090311533938400_jfaf044-B10","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1309\/AJCPF7NFLW8UAJEP","article-title":"Detection of genomic abnormalities in multiple myeloma: the application of FISH analysis in combination with various plasma cell enrichment techniques","volume":"136","author":"Hartmann","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"2025090311533938400_jfaf044-B11","doi-asserted-by":"crossref","first-page":"8287","DOI":"10.1038\/s41598-022-11676-w","article-title":"Cytogenetic testing by fluorescence in situ hybridization is improved by plasma cell sorting in multiple myeloma","volume":"12","author":"Ha","year":"2022","journal-title":"Sci Rep"},{"key":"2025090311533938400_jfaf044-B12","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/1878-0261.12201","article-title":"Microfluidic enrichment of plasma cells improves treatment of multiple myeloma","volume":"12","author":"Zeng","year":"2018","journal-title":"Mol Oncol"},{"key":"2025090311533938400_jfaf044-B13","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.tranon.2018.02.021","article-title":"Combined selection system to lower the cutoff for plasma cell enrichment applied to iFISH analysis in multiple myeloma","volume":"11","author":"Mansilla","year":"2018","journal-title":"Transl Oncol"},{"key":"2025090311533938400_jfaf044-B14","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","article-title":"Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders","volume":"97","author":"Ross","year":"2012","journal-title":"Haematologica"},{"key":"2025090311533938400_jfaf044-B15","first-page":"116","article-title":"Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization","volume":"29","author":"Chen","year":"2007","journal-title":"Exp Oncol"},{"key":"2025090311533938400_jfaf044-B16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/ajcp\/aqad108","article-title":"Superior detection rate of plasma cell FISH using FACS-FISH","volume":"161","author":"Gagnon","year":"2024","journal-title":"Am J Clin Pathol"},{"key":"2025090311533938400_jfaf044-B17","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s12185-012-1021-1","article-title":"Utility of a column-free cell sorting system for separation of plasma cells in multiple myeloma FISH testing in clinical laboratories","volume":"95","author":"Shetty","year":"2012","journal-title":"Int J Hematol"},{"key":"2025090311533938400_jfaf044-B18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1039\/C7IB00183E","article-title":"Isolation of circulating plasma cells from blood of patients diagnosed with clonal plasma cell disorders using cell selection microfluidics","volume":"10","author":"Kamande","year":"2018","journal-title":"Integr Biol U K"},{"key":"2025090311533938400_jfaf044-B19","first-page":"103427","article-title":"Cytogenetics in the management of multiple myeloma: the guidelines from the Groupe Francophone de Cytog\u00e9n\u00e9tique H\u00e9matologique (GFCH)","volume":"71","author":"Daudignon","year":"2023","journal-title":"Curr Res Transl Med"},{"key":"2025090311533938400_jfaf044-B20","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2010-10-299529","article-title":"Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3","volume":"117","author":"Dimopoulos","year":"2011","journal-title":"Blood"},{"key":"2025090311533938400_jfaf044-B21","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"key":"2025090311533938400_jfaf044-B22","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"2025090311533938400_jfaf044-B23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/ijlh.14248","article-title":"Imaging flow cytometric detection of del(17p) in bone marrow and circulating plasma cells in multiple myeloma","volume":"46","author":"Mincherton","year":"2024","journal-title":"Int J Lab Hematol"},{"key":"2025090311533938400_jfaf044-B24","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1136\/jcp-2022-208230","article-title":"IGH cytogenetic abnormalities can be detected in multiple myeloma by imaging flow cytometry","volume":"76","author":"Hui","year":"2023","journal-title":"J Clin Pathol"},{"key":"2025090311533938400_jfaf044-B25","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s10038-023-01136-2","article-title":"Imaging flow cytometry-based multiplex FISH for three IGH translocations in multiple myeloma","volume":"68","author":"Tsukamoto","year":"2023","journal-title":"J Hum Genet"},{"key":"2025090311533938400_jfaf044-B26","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.clml.2022.02.006","article-title":"Incidence and prognostic significance of high-risk cytogenetically abnormalities in multiple myeloma patients in Colombia","volume":"22","author":"Combariza","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025090311533938400_jfaf044-B27","doi-asserted-by":"crossref","first-page":"e1169","DOI":"10.1200\/JOP.19.00639","article-title":"Variability in cytogenetic testing for multiple myeloma: a comprehensive analysis from across the United States","volume":"16","author":"Yu","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"2025090311533938400_jfaf044-B28","doi-asserted-by":"crossref","first-page":"106476","DOI":"10.1016\/j.leukres.2020.106476","article-title":"Deletions and amplifications of the IGH variable and constant regions:a novel prognostic parameter in patients with multiple myeloma","volume":"99","author":"Rabani","year":"2020","journal-title":"Leuk Res"},{"key":"2025090311533938400_jfaf044-B29","doi-asserted-by":"crossref","first-page":"e1363","DOI":"10.1002\/mgg3.1363","article-title":"Cytogenetic and FISH analysis of 93 multiple myeloma Moroccan patients","volume":"8","author":"Hamdaoui","year":"2020","journal-title":"Mol Genet Genomic Med"},{"key":"2025090311533938400_jfaf044-B30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13039-017-0327-3","article-title":"Combination of t(4;14), del(17p13), del(1p32) and 1q21 gain FISH probes identifies clonal heterogeneity and enhances the detection of adverse cytogenetic profiles in 233 newly diagnosed multiple myeloma","volume":"10","author":"Smol","year":"2017","journal-title":"Mol Cytogenet"},{"key":"2025090311533938400_jfaf044-B31","first-page":"3135","article-title":"The utilization of karyotyping, iFISH, and MLPA for the detection of recurrence genetic aberrations in multiple myeloma","volume":"18","author":"Sommaluan","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"key":"2025090311533938400_jfaf044-B32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.bjhh.2016.01.005","article-title":"Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells","volume":"38","author":"Kishimoto","year":"2016","journal-title":"Rev Bras Hematol Hemoter"},{"key":"2025090311533938400_jfaf044-B33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13039-016-0263-7","article-title":"Target fluorescence in-situ hybridization (target FISH) for plasma cell enrichment in myeloma","volume":"9","author":"Ma","year":"2016","journal-title":"Mol Cytogenet"},{"key":"2025090311533938400_jfaf044-B34","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/jcla.21801","article-title":"Antigen expression patterns of plasma cell myeloma: an association of cytogenetic abnormality and International Staging System (ISS) for myeloma","volume":"29","author":"Shin","year":"2015","journal-title":"J Clin Lab Anal"},{"key":"2025090311533938400_jfaf044-B35","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"2025090311533938400_jfaf044-B36","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/apm.12411","article-title":"Clinicopathological features of plasmablastic multiple myeloma: a population-based cohort","volume":"123","author":"M\u00f8ller","year":"2015","journal-title":"APMIS"},{"key":"2025090311533938400_jfaf044-B37","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.hemonc.2015.04.002","article-title":"Detection of 14q32 rearrangements in multiple myeloma, using simultaneous FISH analysis combined with immunofluorescence","volume":"8","author":"Abaza","year":"2015","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"2025090311533938400_jfaf044-B38","doi-asserted-by":"crossref","first-page":"34276","DOI":"10.18632\/oncotarget.5371","article-title":"Detection of recurrent cytogenetic aberrations in multiple myeloma: a comparison between MLPA and iFISH","volume":"6","author":"Zang","year":"2015","journal-title":"Oncotarget"},{"key":"2025090311533938400_jfaf044-B39","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5530\/ami.2015.5.0","article-title":"Fluorescence in situ hybridization on enriched CD138-positive cells in plasma cell myeloma","volume":"2","author":"Shi","year":"2015","journal-title":"Acta Med Int"},{"key":"2025090311533938400_jfaf044-B40","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/bjh.13446","article-title":"Cohort analysis of FISH testing of CD138+ cells in relapsed multiple myeloma: implications for prognosis and choice of therapy","volume":"171","author":"Smith","year":"2015","journal-title":"Br J Haematol"},{"key":"2025090311533938400_jfaf044-B41","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load","volume":"31","author":"Neben","year":"2013","journal-title":"J Clin Oncol"},{"key":"2025090311533938400_jfaf044-B42","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3324\/haematol.2011.060632","article-title":"Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells","volume":"98","author":"Schmidt-Hieber","year":"2013","journal-title":"Haematologica"},{"key":"2025090311533938400_jfaf044-B43","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1751-553X.2012.01433.x","article-title":"Application of an immune-magnetic cell sorting method for CD138-positive plasma cells in FISH analysis of multiple myeloma","volume":"34","author":"Shin","year":"2012","journal-title":"Int J Lab Hematol"},{"key":"2025090311533938400_jfaf044-B44","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1002\/ijc.23455","article-title":"Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma","volume":"122","author":"Hillengass","year":"2008","journal-title":"Int J Cancer"},{"key":"2025090311533938400_jfaf044-B45","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S1525-1578(10)60588-0","article-title":"A practical approach to the detection of prognostically significant genomic aberrations in multiple myeloma","volume":"7","author":"Chen","year":"2005","journal-title":"J Mol Diagn"},{"key":"2025090311533938400_jfaf044-B46","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.cancergencyto.2005.02.015","article-title":"High incidence and intraclonal heterogeneity of chromosome 11 aberrations in patients with newly diagnosed multiple myeloma detected by multiprobe interphase FISH","volume":"161","author":"Cremer","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"key":"2025090311533938400_jfaf044-B47","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1007\/s12032-011-9988-7","article-title":"Fluorescence in situ hybridization analysis of chromosome aberrations in 60 Chinese patients with multiple myeloma","volume":"29","author":"Gao","year":"2012","journal-title":"Med Oncol"},{"key":"2025090311533938400_jfaf044-B48","first-page":"61","article-title":"Modified culture system and combination of FICTION could increase the detection rate of abnormalities in multiple myeloma","volume":"51","author":"Fu","year":"2021","journal-title":"Ann Clin Lab Sci"},{"key":"2025090311533938400_jfaf044-B49","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1002\/hem3.34","article-title":"Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: a favorable prognostic indicator, particularly for R-ISS II patients","volume":"8","author":"Papatsirou","year":"2024","journal-title":"HemaSphere"},{"key":"2025090311533938400_jfaf044-B50","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/jha2.903","article-title":"ciRS-7 circular RNA overexpression in plasma cells is a promising molecular biomarker of unfavorable prognosis in multiple myeloma","volume":"5","author":"Papatsirou","year":"2024","journal-title":"eJHaem"},{"key":"2025090311533938400_jfaf044-B51","doi-asserted-by":"crossref","first-page":"13144","DOI":"10.3390\/ijms222313144","article-title":"A cancer-related microRNA signature shows biomarker utility in multiple myeloma","volume":"22","author":"Papanota","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025090311533938400_jfaf044-B52","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00277-017-3083-x","article-title":"Quantitative PCR: an alternative approach to detect common copy number alterations in multiple myeloma","volume":"96","author":"Chill\u00f3n","year":"2017","journal-title":"Ann Hematol"},{"key":"2025090311533938400_jfaf044-B53","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-014-0105-1","article-title":"Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma","volume":"8","author":"Bolomsky","year":"2015","journal-title":"J Hematol Oncol"},{"key":"2025090311533938400_jfaf044-B54","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1479-5876-11-77","article-title":"Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma","volume":"11","author":"Dementyeva","year":"2013","journal-title":"J Transl Med"},{"key":"2025090311533938400_jfaf044-B55","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3109\/10428194.2010.548535","article-title":"Expression and prognostic significance of Oct2 and Bob1 in multiple myeloma: implications for targeted therapeutics","volume":"52","author":"Toman","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"2025090311533938400_jfaf044-B56","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1182\/blood-2009-01-198408","article-title":"MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma","volume":"113","author":"Roccaro","year":"2009","journal-title":"Blood"},{"key":"2025090311533938400_jfaf044-B57","doi-asserted-by":"crossref","first-page":"6431","DOI":"10.3390\/ijms25126431","article-title":"Molecular long-term analysis of the GMMG-HD4 trial in multiple myeloma\u2014patterns of association of chromosomal aberrations with response and proliferation determining survival in selecting treatments in view of limited resources in low- and middle-income countries","volume":"25","author":"Seckinger","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2025090311533938400_jfaf044-B58","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.3390\/diagnostics12092049","article-title":"Multiple myeloma immunophenotype related to chromosomal abnormalities used in risk assessment","volume":"12","author":"Radzevi\u010dius","year":"2022","journal-title":"Diagnostics"},{"key":"2025090311533938400_jfaf044-B59","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jmoldx.2022.07.002","article-title":"A novel integrated approach for cytogenomic evaluation of plasma cell neoplasms","volume":"24","author":"Aarabi","year":"2022","journal-title":"J Mol Diagn"},{"key":"2025090311533938400_jfaf044-B60","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cancergen.2020.12.003","article-title":"Implementation of cytogenomic microarray with plasma cell enrichment enables better abnormality detection and risk stratification in patients with plasma cell neoplasia than conventional cytogenetics and fluorescence in situ hybridization","volume":"252\u2013253","author":"Chen","year":"2021","journal-title":"Cancer Genet"},{"key":"2025090311533938400_jfaf044-B61","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000361074","article-title":"Utilization of magnetic-activated cell sorting and high-density single nucleotide polymorphism microarrays improves diagnostic yield and prognostic value in clinical testing for patients with multiple myeloma and normal routine chromosome study","volume":"132","author":"Christensen","year":"2014","journal-title":"Acta Haematol"},{"key":"2025090311533938400_jfaf044-B62","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1182\/blood-2015-06-650242","article-title":"Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?","volume":"126","author":"Chretien","year":"2015","journal-title":"Blood"},{"key":"2025090311533938400_jfaf044-B63","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/gcc.22178","article-title":"Can genome array screening replace FISH as a front-line test in multiple myeloma?","volume":"53","author":"Boneva","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"2025090311533938400_jfaf044-B64","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4149\/neo_2014_008","article-title":"Incidence of cytogenetic aberrations in two B lineage subpopulations in multiple myeloma patients analyzed by combination of whole-genome profiling and FISH","volume":"61","author":"Smetana","year":"2014","journal-title":"Neoplasma"},{"key":"2025090311533938400_jfaf044-B65","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/gcc.21982","article-title":"High detection rate of clinically relevant genomic abnormalities in plasma cells enriched from patients with multiple myeloma","volume":"51","author":"Stevens-Kroef","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"2025090311533938400_jfaf044-B66","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1182\/blood-2006-04-018770","article-title":"4q loss is potentially an important genetic event in MM tumorigenesis: identification of a tumor suppressor gene regulated by promoter methylation at 4q13.3, platelet factor 4","volume":"109","author":"Cheng","year":"2007","journal-title":"Blood"},{"key":"2025090311533938400_jfaf044-B67","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1309\/AJCPKW31BAIMVGST","article-title":"Array-based karyotyping in plasma cell neoplasia after plasma cell enrichment increases detection of genomic aberrations","volume":"138","author":"Zehentner","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"2025090311533938400_jfaf044-B68","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3390\/cancers16020358","article-title":"DNA sequencing of CD138 cell population reveals TP53 and RAS-MAPK mutations in multiple myeloma at diagnosis","volume":"16","author":"Dragomir","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2025090311533938400_jfaf044-B69","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12935-024-03470-7","article-title":"Enhancing mutation detection in multiple myeloma with an error-corrected ultra-sensitive NGS assay without plasma cell enrichment","volume":"24","author":"Kim","year":"2024","journal-title":"Cancer Cell Int"},{"key":"2025090311533938400_jfaf044-B70","doi-asserted-by":"crossref","first-page":"1286700","DOI":"10.3389\/fimmu.2023.1286700","article-title":"RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma","volume":"14","author":"Emde-Rajaratnam","year":"2023","journal-title":"Front Immunol"},{"key":"2025090311533938400_jfaf044-B71","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12967-023-04034-5","article-title":"miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma","volume":"21","author":"Papadimitriou","year":"2023","journal-title":"J Transl Med"},{"key":"2025090311533938400_jfaf044-B72","doi-asserted-by":"crossref","first-page":"1110693","DOI":"10.3389\/fonc.2023.1110693","article-title":"Clinical and genomic characterization of Chinese patients with functional high-risk multiple myeloma: a real-world validation study","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"2025090311533938400_jfaf044-B73","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.3390\/cancers15194687","article-title":"Optical genome mapping reveals the complex genetic landscape of myeloma","volume":"15","author":"Gigu\u00e8re","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025090311533938400_jfaf044-B74","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00277-022-04771-5","article-title":"Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cells","volume":"101","author":"Mack","year":"2022","journal-title":"Ann Hematol"},{"key":"2025090311533938400_jfaf044-B75","doi-asserted-by":"crossref","first-page":"663487","DOI":"10.3389\/fgene.2021.663487","article-title":"Cryopreservation preserves cell-type composition and gene expression profiles in bone marrow aspirates from multiple myeloma patients","volume":"12","author":"Chen","year":"2021","journal-title":"Front Genet"},{"key":"2025090311533938400_jfaf044-B76","doi-asserted-by":"crossref","first-page":"14671","DOI":"10.1038\/s41598-021-93835-z","article-title":"Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities","volume":"11","author":"Kriegova","year":"2021","journal-title":"Sci Rep"},{"key":"2025090311533938400_jfaf044-B77","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1158\/1078-0432.CCR-20-2931","article-title":"Chromatin accessibility identifies regulatory elements predictive of gene expression and disease outcome in multiple myeloma","volume":"27","author":"Barwick","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025090311533938400_jfaf044-B78","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/s41416-020-01237-1","article-title":"Prognostic significance of esterase gene expression in multiple myeloma","volume":"124","author":"Kumari","year":"2021","journal-title":"Br J Cancer"},{"key":"2025090311533938400_jfaf044-B79","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/gcc.22848","article-title":"Ultra-low depth sequencing of plasma cell DNA for the detection of copy number aberrations in multiple myeloma","volume":"59","author":"Buedts","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"key":"2025090311533938400_jfaf044-B80","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/cge.13561","article-title":"Low-depth sequencing for copy number abnormalities in multiple myeloma supersedes fluorescent in situ hybridization in scope and resolution","volume":"96","author":"Elnenaei","year":"2019","journal-title":"Clin Genet"},{"key":"2025090311533938400_jfaf044-B81","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41408-018-0160-x","article-title":"Molecular signatures of multiple myeloma progression through single cell RNA-Seq","volume":"9","author":"Jang","year":"2019","journal-title":"Blood Cancer J"},{"key":"2025090311533938400_jfaf044-B82","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cyto.a.23769","article-title":"\u201cImmuno-flowFISH\u201d for the assessment of cytogenetic abnormalities in chronic lymphocytic leukemia","volume":"95","author":"Hui","year":"2019","journal-title":"Cytometry A"},{"key":"2025090311533938400_jfaf044-B83","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","article-title":"Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"J Natl Compr Cancer Netw JNCCN"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/10\/5\/1292\/62952971\/jfaf044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/10\/5\/1292\/62952971\/jfaf044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T15:54:56Z","timestamp":1756914896000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/article\/10\/5\/1292\/8115968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":83,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,4,18]]},"published-print":{"date-parts":[[2025,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jalm\/jfaf044","relation":{},"ISSN":["2475-7241"],"issn-type":[{"value":"2475-7241","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,4,18]]}}}